4,027
Trials as lead sponsor
Most active programmes
The drugs appearing most often across AstraZeneca's recently active trials. Comparator arms are excluded.
- Durvalumab12 trials
- Rilvegostomig8 trials
- Carboplatin6 trials
- Pembrolizumab6 trials
- Cisplatin5 trials
- Tremelimumab5 trials
Upcoming readouts
Next primary completion dates among AstraZeneca's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jan 2027A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally …Phase 2
- Apr 2027CAMBRIA-1: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adju…Phase 3
- Apr 2027PRISM: Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyPhase 2
- Jun 2027DG-03: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastri…Phase 2
- Jun 2027Umbriel: Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolle…Phase 2
- Jun 2027CANTOR: A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 2
Top therapeutic areas
Conditions studied most often across AstraZeneca's recently active trials.
- Asthma8 trials
- Breast Cancer7 trials
- Type 2 Diabetes Mellitus4 trials
- Non-Small Cell Lung Cancer4 trials
- Chronic Lymphocytic Leukemia3 trials
- Hepatocellular Carcinoma3 trials
AstraZeneca trials
The 50 most significant of AstraZeneca's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| CHOICECHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCNCT07413757 | — | Not yet scored | OngoingRecruiting | 590 est. | 31 Jul 2026 |
| ARTEMIDE-01A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCNCT04995523AZD2936 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 212 est. | 28 Aug 2026 |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerNCT03423628Radiation Therapy | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 159 est. | 3 Sept 2026 |
| OverTTuReOverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisNCT06355934 | — | Not yet scored | OngoingRecruiting | 52,121 est. | 30 Sept 2026 |
| ALSACStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology ClinicsNCT07315958 | — | Not yet scored | OngoingRecruiting | 1,000 est. | 30 Sept 2026 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With DyslipidemiaNCT06980428AZD4954 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 136 est. | 4 Dec 2026 |
| Pan HER2A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsNCT07404202 | — | Not yet scored | OngoingRecruiting | 2,100 est. | 31 Dec 2026 |
| AQUALISAQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseNCT06548152 | — | Not yet scored | OngoingRecruiting | 120 est. | 31 Dec 2026 |
| ROSY-DRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabNCT05303532Durvalumab | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 214 est. | 31 Dec 2026 |
| EvolutionHF-DEReal-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyNCT06336330 | — | Locked · track to reveal | OngoingActive, not recruiting | 831 est. | 31 Dec 2026 |
| AZURE-HeFHA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHNCT07000136AZD0780 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 473 est. | 4 Jan 2027 |
| AZURE-LDLA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventNCT07000123AZD0780 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 3,103 est. | 11 Jan 2027 |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaNCT07069712AZD0901 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 100 est. | 28 Jan 2027 |
| ANCHORCombination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareNCT06422689Albuterol and budesonide inhalation aerosol | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 1,511 est. | 3 Feb 2027 |
| PROceedReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738 | — | Not yet scored | OngoingRecruiting | 250 est. | 14 Feb 2027 |
| GenometA Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)NCT07613424NGS testing | Na | Locked · track to reveal | OngoingRecruiting | 1,000 est. | 31 Mar 2027 |
| PEAKA Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)NCT06749457AZD7760 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 231 est. | 2 Apr 2027 |
| CAMBRIA-1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951Camizestrant | Phase 3 | Locked · track to reveal | OngoingRecruiting | 4,300 est. | 20 Apr 2027 |
| PRISMPrevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyNCT07285213AZD5148 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 230 est. | 20 Apr 2027 |
| FRONTEDGEObservational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in ItalyNCT06948396Tezepelumab | — | Locked · track to reveal | OngoingActive, not recruiting | 315 est. | 30 May 2027 |
| DG-03Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596Fluorouracil (5-FU) | Phase 2 | Locked · track to reveal | OngoingRecruiting | 450 est. | 1 Jun 2027 |
| UmbrielDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263Tozorakimab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 540 est. | 7 Jun 2027 |
| CANTORA Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerNCT06792695Volrustomig | Phase 2 | Locked · track to reveal | OngoingRecruiting | 80 est. | 30 Jun 2027 |
| ATLANTISThe Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in RussiaNCT07390240 | — | Not yet scored | OngoingRecruiting | 55 est. | 30 Jun 2027 |
| PHRASE-HFNon-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in GermanyNCT06675552 | — | Not yet scored | OngoingRecruiting | 438 est. | 30 Jun 2027 |
| A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityNCT07013643AZD6234 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | 9 Jul 2027 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864Dato-DXd | Phase 3 | Locked · track to reveal | OngoingRecruiting | 625 est. | 28 Jul 2027 |
| A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBENCT07245407Participant Follow-up | — | Not yet scored | OngoingRecruiting | 320 est. | 29 Jul 2027 |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaNCT06106945AZD0305 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 226 est. | 16 Aug 2027 |
| IMFINZI-subQA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabNCT07391670SC durvalumab + rHu | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 30 Aug 2027 |
| A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese AdultsNCT07612813AZD7760 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 18 est. | 13 Sept 2027 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482AZD8205 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 460 est. | 29 Sept 2027 |
| SCOPeStudy That Will Evaluate the Brazilian Population With COPD.NCT06780046 | — | Not yet scored | OngoingRecruiting | 693 est. | 30 Sept 2027 |
| ACADIAEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaNCT06307665BDA MDI | Phase 3 | Locked · track to reveal | OngoingRecruiting | 440 est. | 13 Oct 2027 |
| EXPLOREReal-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerNCT06727227trastuzumab deruxtecan | — | Locked · track to reveal | OngoingRecruiting | 138 est. | 31 Oct 2027 |
| PRESTOA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738AZD6793 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 987 est. | 5 Nov 2027 |
| CRIUS-1First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerNCT07529717AZD8359 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 42 est. | 17 Nov 2027 |
| PULSEA Study of AZD4063 in PLN R14del Dilated CardiomyopathyNCT07241104AZD4063 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 31 est. | 22 Nov 2027 |
| SERENA-1bStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerNCT07427394Camizestrant | Phase 2 | Locked · track to reveal | OngoingRecruiting | 24 est. | 3 Dec 2027 |
| INTERSTELLARINTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseNCT06314282 | — | Not yet scored | OngoingRecruiting | 200 est. | 31 Dec 2027 |
| NEREUSClinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaNCT07088991 | — | Not yet scored | OngoingRecruiting | 200 est. | 31 Mar 2028 |
| ARESReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in RussiaNCT07399665 | — | Locked · track to reveal | OngoingRecruiting | 110 est. | 31 Mar 2028 |
| ALLightStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaNCT07109219AZD4512 monotherapy | Phase 1 | Locked · track to reveal | OngoingRecruiting | 83 est. | 28 Apr 2028 |
| Eluminate-2A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213Elecoglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,200 est. | 23 May 2028 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)NCT07073547AZD0120 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 26 May 2028 |
| Eluminate-5A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109Elecoglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 5 Jul 2028 |
| Eluminate-4A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135Elecoglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 900 est. | 13 Jul 2028 |
| Eluminate-1A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044Elecoglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 800 est. | 14 Jul 2028 |
| BLOSSOMAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsNCT05835310Anifrolumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 100 est. | 5 Oct 2028 |
| PACIFIC-4Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationNCT03833154Durvalumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 724 est. | 31 Oct 2028 |